Biomea Fusion, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Redwood city, calif., april 01, 2024 (globe newswire) -- biomea fusion, inc. (nasdaq: bmea) (“biomea” or the “company”), a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases, today announced that on april 1, 2024, the compensation committee of biomea's board of directors granted two new employees non-qualified stock options to purchase an aggregate of 6,500 shares of the company's common stock. the shares underlying each employee's stock options will vest 1/16 on a quarterly basis over four years, in each case subject to each such employee's continued employment with the company on such vesting dates...

Bmf-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes

Redwood city, calif., april 01, 2024 (globe newswire) -- biomea fusion, inc. (“biomea” or “the company”) (nasdaq: bmea), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, reported fourth quarter and full year 2023 financial results and corporate highlights.

Three clinical data sets from the dose escalation phase of covalent-111 to be presented at the 17 th annual attd conference highlighting bmf-219's novel mechanism of action in patients with type 2 diabetes

Redwood city, calif., march 01, 2024 (globe newswire) -- biomea fusion, inc. (nasdaq: bmea) (“biomea” or the “company”), a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases, today announced that on march 1, 2024, the compensation committee of biomea's board of directors granted two new employees non-qualified stock options to purchase an aggregate of 7,000 shares of the company's common stock. the shares underlying each employee's stock options will vest 1/16 on a quarterly basis over four years, in each case subject to each such employee's continued employment with the company on such vesting dates...

There's a simple reason why short-squeeze stocks to buy represent a powerful catalyst: they're intuitive and easier to engage. Buying something and hoping that it appreciates in value represents an organically sensible strategy.

Financial advisors rarely if ever recommend speculative stocks because they don't want to get sued. Let's be real here.

REDWOOD CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced that Thomas Butler, Biomea Fusion's Chief Executive Officer and Chairman of the Board, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 from 8:15 am – 8:55 am PST, and that Biomea management will hold 1x1 meetings during the conference January 8 – 11.

BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes

BMF-219 is an investigational novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure type 2 diabetes BMF-219 is an investigational novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure type 2 diabetes

Biomea Fusion is a clinical-stage biotech company developing covalent small molecule inhibitors, with its lead asset BMF-219 showing promising initial phase 2 data for Type 2 diabetes. The company's core strategy is to leverage its proprietary FUSION System platform to develop covalent inhibitors for other cancer targets. The company's Phase 1/2 study for BMF-219 showed significant reductions in blood sugar levels in Type 2 diabetes patients, with the results maintained up to 12 weeks after treatment. However, some toxicity signals were present, leading to a rethinking of the dosing. Further trials are needed to validate the platform and finalize dose escalation.

A year removed from its $20 IPO of April 2021, Biomea Fusion, Inc. NASDAQ: BMEA faded into penny stock land as investors lost their appetite for high-risk biotechnology stocks. Approximately a year later, it skyrocketed more than 15 times.

Shares of Biomea Fusion Inc. BMEA, -5.89% jumped 17% in premarket trading Monday after the clinical-stage biopharmaceutical company released new clinical data on its investigational covalent menin inhibitor for patients with type 2 diabetes. The data supports the ability of the treatment, BMF-219, to address a root cause of the disease, beta cell loss, Biomea CEO and chairman Thomas Butler said in a statement.

REDWOOD CITY, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced that it will present new clinical data from the ongoing Phase II portion of its COVALENT-111 trial, which is evaluating BMF-219 as a potential treatment for patients with type 2 diabetes, in a late-breaking poster presentation at the 2023 American Diabetes Association's (ADA's) 83rd Scientific Sessions, to be held June 23 – 26, 2023 at the San Diego Convention Center in San Diego, CA...

BMEA develops oral covalent small molecules for cancer and diabetes. Its lead asset is a menin inhibitor.